Novartis Ag

The Scripps Research Institute

Michael Joseph Kadan

Carlos F Barbas, Iii

Roger Renzo Beerli

Gary Michael Ksander

Kathryn Rene Bracken

Joseph Ernest De Los Angeles

Dennis Bryan Zerby

Ying Huang

Fusion proteins for use as ligand-dependent transcriptional regulators are provided. The fusion proteins include a nucleotide binding domain operatively linked to a ligand-binding domain. They also can include a transcription regulating domain. The nucleotide binding domain is a zinc-finger peptide that binds to a targeted contiguous nucleotide sequence of from 3 to about 18 nucleotides are provided. The fusion proteins are used for gene therapy. Also provided are polynucleotides encoding the fusion proteins, expression vectors, and transfected cells.

Ligand activated transcriptional regulator proteins

Mutants of steroid receptor ligand binding domains and synthetic ligands which have specific binding affinities for these receptors are provided. The use of these LBD-ligand combinations for construction of selective 'molecular gene switches' is disclosed. Methods of regulating gene function using these switches are provided.

Nucleic acids encoding estrogen receptor ligand binding domain variants

Growing community of inventors

Adamstown, MD, United States of America

Michael Joseph Kadan